Literature DB >> 11676349

Radiologic, pathologic and molecular attributes of two types of papillary renal adenocarcinomas.

J H Mydlo1, R Weinstein, R Misseri, C Axiotis, W Thelmo.   

Abstract

OBJECTIVE: Most papillary renal tumors are not as aggressive as clear cell carcinomas and thus carry a better prognosis. However, several reports in the literature have demonstrated a subset of patients with papillary tumors that have a more aggressive biology and advanced stage at presentation. We compared several parameters of these subsets of renal tumors in an effort to characterize these lesions. PATIENTS AND METHODS: We reviewed 391 cases of nephrectomies that were performed for cancer over a 20-year period from four institutions. Of these, 41 were documented as papillary adenocarcinomas. We reviewed these cases with respect to stage at presentation, size, vascularity on (computerized tomography) CT scan, histology, and cytokeratin immunohistology.
RESULTS: Thirty-two of the lesions presented in the fifth, sixth, seventh and eighth decades of life (Type I), while most of the remaining 9 tumors (Type II) presented in the fourth decade of life, and in more advanced stages. Tumor volumes ranged from 84 cm3 to 1660 cm3. Type I tumors had an average size of 515 cm3 and an enhancement on CT of 36 +/- 4 Hounsfield units, compared with Type II tumors which had an average size of 164 cm3 and an enhancement on CT of 92 +/- 8 Hounsfield units. Type II tumors also had a higher mean Fuhrman score of nuclear pleomorphism than Type I, and a greater expression of cytokeratin.
CONCLUSIONS: We found that the more common Type I variant of papillary renal adenocarcinoma was less vascular on CT scan, larger in size, and had a lower amount of nuclear pleomorphism as well as decreased expression of cytokeratin 7. The more aggressive biological variant, Type II, presented in the earlier decades of life, with a smaller, but more vascular, cancer and had a greater nuclear pleomorphism. Nuclear pleomorphism still appears to have the best prognostic assessment. However, other molecular and genetic parameters of these tumors, as well as long-term survival data will be necessary to determine the significance of these findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676349     DOI: 10.1080/003655901750425819

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma.

Authors:  Suat Keskin; Zeynep Keskin; Hakan Hakki Taskapu; Havva Kalkan; Mehmet Kaynar; Necdet Poyraz; Hatice Toy
Journal:  BMC Urol       Date:  2014-11-26       Impact factor: 2.264

2.  Multimodality Imaging Characteristics of the Common Renal Cell Carcinoma Subtypes: An Analysis of 544 Pathologically Proven Tumors.

Authors:  Winnie Fu; Guan Huang; Zaahir Moloo; Safwat Girgis; Vimal H Patel; Gavin Low
Journal:  J Clin Imaging Sci       Date:  2016-12-29

3.  Differential Diagnosis of Type 1 and Type 2 Papillary Renal Cell Carcinoma Based on Enhanced CT Radiomics Nomogram.

Authors:  Yankun Gao; Xingwei Wang; Shihui Wang; Yingying Miao; Chao Zhu; Cuiping Li; Guoquan Huang; Yan Jiang; Jianying Li; Xiaoying Zhao; Xingwang Wu
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

4.  A Clinical Radiomics Nomogram Was Developed by Integrating Radiomics Signatures and Clinical Variables to Distinguish High-Grade ccRCC from Type 2 pRCC.

Authors:  Yankun Gao; Xiaoying Zhao; Xia Wang; Chao Zhu; Cuiping Li; Jianying Li; Xingwang Wu
Journal:  J Oncol       Date:  2022-08-26       Impact factor: 4.501

5.  Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.

Authors:  Jian He; Kefeng Zhou; Bin Zhu; Gutian Zhang; Xiaogong Li; Hongqian Guo; Weidong Gan; Zhengyang Zhou; Tian Liu
Journal:  Biomed Res Int       Date:  2015-11-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.